Heather Turner, LB Pharmaceuticals CEO
January 8, 2025 07:00 AM EST
R&D

With schiz­o­phre­nia tri­al suc­cess, LB Phar­ma­ceu­ti­cals thinks about Phase 3 and next fund­ing

Max Gelman

Senior Editor

A pri­vate start­up look­ing to bring an old schiz­o­phre­nia drug class to the US has re­leased new Phase 2 da­ta and aims to start a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Coave rais­es €32M Se­ries A de­spite be­ing two years away from the clin­ic

Af­ter lack­lus­ter 2024, bio­phar­ma in­dus­try prays stalled M&A will fi­nal­ly move in­to gear

Astel­las stops de­vel­op­ing au­tol­o­gous cell ther­a­py us­ing tech from Xyphos buy­out

A service from the Financial Times